Improving Immunotherapy for Colorectal Cancer Using Dendritic Cells Combined With Anti-Programmed Death-Ligand In�vitro

Oncology Letters - Greece
doi 10.3892/ol.2018.7978
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

JAMA Dermatology
DermatologyMedicine
2016English

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

Clinical Cancer Research
Cancer ResearchOncology
2012English

In�vitro Generation of Cytotoxic T�lymphocyte Response Using Dendritic Cell Immunotherapy in Osteosarcoma

Oncology Letters
Cancer ResearchOncology
2016English

Clinicopathological Significance and Prognostic Implication of Programmed Death-1 Ligand 2 Expression in Colorectal Cancer

International Journal of Biological Markers
OncologyCancer ResearchClinical BiochemistryForensic MedicineMedicinePathology
2019English

Cancer Immunotherapy With Immunomodulatory Anti-Cd137 and Anti-Pd-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

Cancer Discovery
Oncology
2015English

Antitumor Effects of the Silencing of Programmed Cell Death Ligand�1 in Colorectal Cancer via Immunoregulation

Oncology Reports
MedicineCancer ResearchOncology
2018English

Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy

Matters
2017English

Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers

British Journal of Cancer
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy